ライフサイエンスコーパス: coronary artery bypass graft

1 gulation of miR-1 in the right atrium during coronary artery bypass graft.

2 nts with previous cardiac surgery, including coronary artery bypass grafts.

3 was achieved in 6 of 10 patients with prior coronary artery bypass grafts.

4 m were obtained from 306 patients undergoing coronary artery bypass grafting.

5 rone that was similar to patients undergoing coronary artery bypass grafting.

6 .0% of patients and were most frequent after coronary artery bypass grafting.

7 nosis (AS) who underwent AVR with or without coronary artery bypass grafting.

8 e atrial fibrillation (PoAF) is common after coronary artery bypass grafting.

9 native coronary artery disease 1 year after coronary artery bypass grafting.

10 rel or aspirin plus placebo for 1 year after coronary artery bypass grafting.

11 ary intervention, and 2832 (10.7%) underwent coronary artery bypass grafting.

12 , 57,961 patients underwent primary isolated coronary artery bypass grafting.

13 y high (50%), and 6 (13%) required emergency coronary artery bypass grafting.

14 clude percutaneous coronary intervention and coronary artery bypass grafting.

15 of 2 arterial grafts in patients undergoing coronary artery bypass grafting.

16 should be considered more frequently during coronary artery bypass grafting.

17 this contributes to clinical outcomes after coronary artery bypass grafting.

18 ions, contemporary practice, and outcomes of coronary artery bypass grafting.

19 improve short- and long-term outcomes after coronary artery bypass grafting.

20 ion, percutaneous coronary intervention, and coronary artery bypass grafting.

21 and improved survival in patients undergoing coronary artery bypass grafting.

22 scending (LAD) artery in patients undergoing coronary artery bypass grafting.

23 Concomitant procedures included coronary artery bypass grafting (13%), mitral valve repa

24 This included 10 coronary artery bypass grafts, 2 epicardial implantable

25 rcutaneous coronary intervention: 28 011 and coronary artery bypass grafting: 6277).

26 ne surgery (9.8%), herniorrhaphy (7.4%), and coronary artery bypass grafting (7.0%).

27 nary intervention (1.2 versus 3.2 hours) and coronary artery bypass grafting (7.9 versus 55.9 hours).

28 At 12 to 18 months post-coronary artery bypass grafting, 782 of 1828 (42.8%) pat

29 vated troponin levels between studies, prior coronary artery bypass grafting, a left ventricular ejec

30 scharged after 10 major surgical procedures (coronary artery bypass grafting, abdominal aortic aneury

31 on adjusted OR: 0.74; 95% CI: 0.73 to 0.75) (coronary artery bypass grafting adjusted OR: 0.61; 95% C

32 There also were >18,000 fewer coronary artery bypass graft admissions in 2012 than in

33 cic Surgeons records; 162 572 (61%) isolated coronary artery bypass grafting admissions constituted t

34 no clear guidelines on the use of the RA in coronary artery bypass grafting after its catheterizatio

35 procedures (stress imaging, angiography, or coronary artery bypass grafting) after the index PCI wer

36 Procedural need for emergent coronary artery bypass graft and mortality rates were lo

37 ariable cost in patients undergoing elective coronary artery bypass graft and valve surgeries.

38 needed to risk stratify patients undergoing coronary artery bypass grafting and identify candidates

39 Two cohorts of patients who underwent coronary artery bypass grafting and received perioperati

40 In-hospital coronary artery bypass grafting and renal insufficiency

41 cribes 20-year results of RA grafts used for coronary artery bypass grafting and the effects of RA re

42 Of 10 633 adults who underwent coronary artery bypass grafting and valve surgery betwee

43 fibrillation (AF) in patients who underwent coronary artery bypass grafting and were treated with pe

44 Patients having coronary artery bypass grafting and/or cardiac valve rep

45 aneurysm repair, $5309.78 (17% increase) for coronary artery bypass graft, and $7813.53 (53% increase

46 farction, unstable and stable angina, recent coronary artery bypass graft, and peripheral arterial di

47 primary percutaneous coronary intervention, coronary artery bypass grafting, and medical therapy, re

48 l artery (RA) is a commonly used conduit for coronary artery bypass grafting, and recent studies have

49 jury in percutaneous coronary interventions, coronary artery bypass grafting, and reperfused acute my

50 ubgroup analysis of patients undergoing only coronary artery bypass grafting, and results were simila

51 impact on the function of RA grafts used in coronary artery bypass grafting, and there is now compre

52 atinine clearance <60 mL/min, treatment with coronary artery bypass grafting, anemia, and diabetes me

53 These findings may help guide post-coronary artery bypass grafting antiplatelet therapy.

54 resection, abdominal aortic aneurysm repair, coronary artery bypass graft, aortic valve replacement,

55 1 patients aged 60 years or older undergoing coronary artery bypass graft, aortic valve surgery, mitr

56 beneficiaries aged 65 to 99 years undergoing coronary artery bypass grafting, aortic valve repair, or

57 In the APTITUDE-Coronary Artery Bypass Graft (APTITUDE-CABG) study, vaso

58 sion of native coronary artery disease after coronary artery bypass grafting are unknown.

59 bare metal stents, 19% with DES, and 6% with coronary artery bypass grafting at 1 year.

60 s should be maximized in patients undergoing coronary artery bypass grafting because they have excell

61 tion, in-hospital mortality was higher after coronary artery bypass grafting, but long-term survival

62 uch that patients with low CFR who underwent coronary artery bypass grafting, but not percutaneous co

63 ed to compare the long-term effectiveness of coronary artery bypass graft (CABG) and percutaneous cor

64 ercutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) are an unintended co

65 PCI) within 2 years and within 5 years after coronary artery bypass graft (CABG) in the absence of ne

66 coronary artery disease (LMCAD) treated with coronary artery bypass graft (CABG) or percutaneous coro

67 cutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) routinely exclude pa

68 Racial disparities in mortality rates after coronary artery bypass graft (CABG) surgery are well est

69 e (CAD) had improved long-term outcomes with coronary artery bypass graft (CABG) surgery compared wit

70 orary drug-eluting stent (DES) compared with coronary artery bypass graft (CABG) surgery in patients

71 The effect on post-operative outcomes after coronary artery bypass graft (CABG) surgery is not clear

72 ss of coronary revascularization with either coronary artery bypass graft (CABG) surgery or percutane

73 tus and multivessel coronary artery disease, coronary artery bypass graft (CABG) surgery resulted in

74 gnosis and a greater prognostic benefit from coronary artery bypass graft (CABG) surgery than those w

75 recent studies have compared the outcomes of coronary artery bypass graft (CABG) surgery with percuta

76 function and vein graft failure (VGF) after coronary artery bypass graft (CABG) surgery.

77 d improve patients' prognosis after elective coronary artery bypass graft (CABG) surgery.

78 trial, yet it is now a quality standard for coronary artery bypass graft (CABG) surgery.

79 Data are sparse on long-term mortality after coronary artery bypass graft (CABG) surgery.

80 Multiple studies have compared coronary artery bypass graft (CABG) with percutaneous co

81 d with reduced morbidity and mortality after coronary artery bypass graft (CABG).

82 hropometrics) of CR post-HT compared to post-coronary artery bypass graft (CABG).

83 lectomy (189229 patients at 1876 hospitals), coronary artery bypass grafting (CABG) (218940 patients

84 after the procedure between on- and off-pump coronary artery bypass grafting (CABG) (n = 6; low SOE),

85 injury (AKI) is a common complication after coronary artery bypass grafting (CABG) and is associated

86 n with percutaneous coronary intervention or coronary artery bypass grafting (CABG) and its long-term

87 o address the most recent evidence bases for coronary artery bypass grafting (CABG) and stenting in p

88 re, and coronary artery disease suitable for coronary artery bypass grafting (CABG) are at higher ris

89 ved ejection fraction in patients undergoing coronary artery bypass grafting (CABG) are limited and i

90 The long-term outcomes of off-pump coronary artery bypass grafting (CABG) are the subject o

91 nd MV replacement and repair with or without coronary artery bypass grafting (CABG) between 2007 and

92 coronary syndromes (ACS) undergoing isolated coronary artery bypass grafting (CABG) compared with asp

93 telet therapy (DAPT) in patients who undergo coronary artery bypass grafting (CABG) following acute c

94 h left main coronary artery (LMCA) stenosis, coronary artery bypass grafting (CABG) has been the stan

95 eft anterior descending (LAD) at reoperative coronary artery bypass grafting (CABG) improves patient

96 mited data regarding long-term results after coronary artery bypass grafting (CABG) in young adults.

97 enosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and oft

98 Coronary artery bypass grafting (CABG) is the standard t

99 Patients undergoing coronary artery bypass grafting (CABG) must often see mu

100 It is unknown if coronary artery bypass grafting (CABG) or percutaneous c

101 unclear whether revascularization by either coronary artery bypass grafting (CABG) or percutaneous c

102 Today's coronary artery bypass grafting (CABG) population appear

103 d data on outcomes of patients with previous coronary artery bypass grafting (CABG) presenting with S

104 icated in stroke risk at the time of on-pump coronary artery bypass grafting (CABG) procedures.

105 Coronary artery bypass grafting (CABG) remains the stand

106 Current guidelines suggest that coronary artery bypass grafting (CABG) should be the pre

107 omized trial data support the superiority of coronary artery bypass grafting (CABG) surgery over perc

108 ete revascularization in patients undergoing coronary artery bypass grafting (CABG) surgery.

109 al, 33 patients who were undergoing off-pump coronary artery bypass grafting (CABG) were randomly ass

110 ailure) trial compared a strategy of routine coronary artery bypass grafting (CABG) with guideline-ba

111 th from randomized trials that have compared coronary artery bypass grafting (CABG) with percutaneous

112 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), on long-term out

113 cular (LV) biopsies from patients undergoing coronary artery bypass grafting (CABG), only the activat

114 t alone, percutaneous coronary intervention, coronary artery bypass grafting (CABG), or CABG plus mit

115 In coronary artery bypass grafting (CABG), the combined use

116 ent literature on standardization of care in coronary artery bypass grafting (CABG), with particular

117 nd with a higher risk of complications after coronary artery bypass grafting (CABG).

118 an increased risk of adverse outcomes after coronary artery bypass grafting (CABG).

119 predict cardiovascular events or death after coronary artery bypass grafting (CABG).

120 cutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG).

121 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

122 s may present an alternative to conventional coronary artery bypass grafting (CABG).

123 levation acute coronary syndromes undergoing coronary artery bypass grafting (CABG).

124 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); a small percenta

125 afts intraoperatively in patients undergoing coronary artery bypass grafting (CABG); however, studies

126 inically significant bleeding not related to coronary artery bypass grafting (CABG; major, minor, or

127 ove clinical outcomes in patients undergoing coronary-artery bypass graft (CABG) surgery is not known

128 The survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to guidelin

129 In a trial comparing coronary-artery bypass grafting (CABG) alone with CABG p

130 he benefits of adding mitral-valve repair to coronary-artery bypass grafting (CABG) are uncertain.

131 ral internal thoracic (mammary) arteries for coronary-artery bypass grafting (CABG) may improve long-

132 Coronary-artery bypass grafting (CABG) surgery may be pe

133 s have shown lower long-term mortality after coronary-artery bypass grafting (CABG) than after percut

134 The benefits of coronary-artery bypass grafting (CABG) without cardiopul

135 nary artery disease are usually treated with coronary-artery bypass grafting (CABG).

136 ive, high-risk cardiac surgery (ie, combined coronary artery bypass graft [CABG] surgery and valve re

137 elines recommend surgical revascularization (coronary artery bypass graft [CABG]) over percutaneous c

138 theterization followed by treatment (ie, 128 coronary artery bypass graft [CABG], 150 percutaneous co

139 ronary chronic total occlusions (CTOs) after coronary artery bypass grafts (CABGs) is higher than in

140 ld have on previously cannulated RAs used as coronary artery bypass grafting conduits.

141 erwent percutaneous coronary intervention or coronary artery bypass graft due to significant stenosis

142 e., no percutaneous coronary intervention or coronary artery bypass grafting during the index hospita

143 CABG from the European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG) registry betwee

144 lve replacement and aortic valve replacement+coronary artery bypass grafting, extensive updating usin

145 A total of 508 patients who underwent coronary artery bypass grafting for cardiogenic shock co

146 In patients undergoing coronary artery bypass grafting, genetic variation in GR

147 ndomized controlled trial comparing HCR with coronary artery bypass grafting has recently emerged in

148 phy, percutaneous coronary intervention, and coronary artery bypass grafting) has expanded, yet natio

149 ternal mammary artery (BIMA) conduits during coronary artery bypass grafting have better long-term su

150 Nearly 50% of patients undergoing coronary artery bypass grafting have diabetes.

151 0.64; 95% confidence interval, 0.60-0.69) or coronary artery bypass grafting (hazard ratio, 0.53; 95%

152 inpatient surgery among patients undergoing coronary artery bypass grafting, hip replacement, back s

153 d national Medicare beneficiaries undergoing coronary artery bypass grafting in 2008 to 2010 (N = 255

154 ns about competitive flow and the benefit of coronary artery bypass grafting in intermediate LAD sten

155 ial infarction is an indication for emergent coronary artery bypass grafting in patients not amenable

156 antly higher risk of mortality and emergency coronary artery bypass grafting in patients treated by n

157 Emergency coronary artery bypass grafting in patients with acute m

158 ader spectrum of patients who are undergoing coronary artery bypass grafting in routine practice.

159 n, and percutaneous coronary intervention or coronary artery bypass grafting in the preceding 12 mont

160 previous cerebrovascular event, in-hospital coronary artery bypass grafting, in-hospital bleeding, a

161 of a third arterial conduit in patients with coronary artery bypass grafting is not associated with h

162 cardiac surgery, especially the presence of coronary artery bypass grafts, is thought to preclude pe

163 major bleeding and a 6-fold increase in non-coronary artery bypass graft life-threatening bleeding w

164 e potential added advantage of multiarterial coronary artery bypass graft (MA-CABG).

165 -main disease who underwent primary isolated coronary artery bypass grafting (MAG, n = 5580; LITA+SVG

166 death, myocardial infarction, stroke, or non-coronary artery bypass graft major bleeding.

167 ies undergoing colectomy, lung resection, or coronary artery bypass grafting (n = 1,033,255) to creat

168 nts (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery bypass grafting (n=8/group).

169 98), and had no significant effect on adding coronary artery bypass grafting (odds ratio, 0.929; 95%

170 onfidence interval, 1.02-1.19) and emergency coronary artery bypass grafting (odds ratio, 1.32; 95% c

171 7% men) were included, with a mean time from coronary artery bypass graft of 12+/-5 years.

172 n (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior des

173 ose in STICH Hypothesis 2 were randomized to coronary artery bypass grafting or coronary artery bypas

174 d follow-up angiography 12 to 18 months post-coronary artery bypass grafting or earlier clinically dr

175 erences in coronary revascularization rates (coronary artery bypass grafting or percutaneous coronary

176 ied, having a primary diagnosis of emergency coronary artery bypass grafting or valve replacement, an

177 nce intervals, 1.02-1.03; P<0.001), previous coronary artery bypass graft (OR, 1.44; 95% confidence i

178 underwent abdominal aortic aneurysm repair, coronary artery bypass graft, or colon resection for neo

179 y alone, percutaneous coronary intervention, coronary artery bypass grafting, or more information req

180 Among 6497 post- coronary artery bypass graft participants, mean and medi

181 120 coronary artery bypass graft patients aged 45-65 years u

182 ed sound therapy on agitation and anxiety on coronary artery bypass graft patients during weaning fro

183 on in weaning from mechanical ventilation in coronary artery bypass graft patients.

184 In-hospital mortality for coronary artery bypass grafting patients was 8.2%; all-c

185 nditions, and in-hospital procedures such as coronary artery bypass grafting, percutaneous coronary i

186 as fatal or nonfatal myocardial infarction, coronary artery bypass grafting, percutaneous translumin

187 ge, left atrial size, diabetes, and previous coronary artery bypass graft procedure were significantl

188 implantation were more likely to have prior coronary artery bypass graft procedures, higher peak tro

189 in injection into epicardial fat pads during coronary artery bypass graft provided substantial atrial

190 We identified patients who underwent coronary artery bypass grafting, pulmonary lobectomy, en

191 30-day readmissions for patients undergoing coronary artery bypass grafting, pulmonary lobectomy, en

192 ade: r=0.46; P=0.0001) and SAVR (concomitant coronary artery bypass grafting: r=-0.33; P=0.03).

193 tes (39.2% versus 13.2%; P<0.001) and higher coronary artery bypass graft rates (9.5% versus 4.4%; P<

194 Despite higher PCI and coronary artery bypass graft rates for Medicare patients

195 issions Reduction Program formula using only coronary artery bypass grafting readmissions with a 3% m

196 ADBRs included non-coronary artery bypass graft-related Thrombolysis In Myo

197 Coronary artery bypass grafting remains one of the most

198 conduit improves outcomes after multivessel coronary artery bypass grafting remains unclear.

199 ery disease with traditional single-arterial coronary artery bypass graft (SA-CABG) has been associat

200 Aortic atheroma (TAVI) and concomitant coronary artery bypass grafting (SAVR) are independent r

201 Coronary artery bypass grafting seems to be the preferre

202 ty of Thoracic Surgeons composite rating for coronary artery bypass grafting (STS-CABG), and Centers

203 Coronary artery bypass grafting success is limited by ve

204 ) between CFR and early revascularization by coronary artery bypass grafting, such that patients with

205 Hospitals that performed 1 or more coronary artery bypass graft surgeries in a given calend

206 retrospective analysis of 47 984 consecutive coronary artery bypass grafting surgeries performed from

207 Among the study population, 1482 coronary artery bypass grafting surgeries with BIMA were

208 s driven by BARC major bleeding unrelated to coronary artery bypass graft surgery (1.6% vs 2.3%, RR 0

209 nary artery disease (64.4% vs. 83.7%), prior coronary artery bypass graft surgery (19.8% vs. 61.2%),

210 ence of diabetes mellitus (45%) and previous coronary artery bypass graft surgery (34%).

211 terval [CI], 1.04-1.04; P<0.001); history of coronary artery bypass graft surgery (beta=1.32; CI, 1.2

212 Coronary artery bypass graft surgery (CABG) compared wit

213 h (SCD) in patients with heart failure after coronary artery bypass graft surgery (CABG) has not been

214 New-onset atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG) is associate

215 Guidelines recommend coronary artery bypass graft surgery (CABG) over percuta

216 se in Individuals With Diabetes) trial found coronary artery bypass graft surgery (CABG) was associat

217 vessel or left main coronary artery disease, coronary artery bypass graft surgery (CABG) was associat

218 Current guidelines recommend coronary artery bypass graft surgery (CABG) when treatin

219 dysfunction have higher operative risk with coronary artery bypass graft surgery (CABG).

220 g complications or who underwent in-hospital coronary artery bypass graft surgery (N = 2,258,711 visi

221 , 0.61; 95% confidence interval, 0.55-0.67), coronary artery bypass graft surgery (n=1077; hazard rat

222 ed with 809 with WCDs (90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.0

223 However, there is paucity of data comparing coronary artery bypass graft surgery against newer gener

224 nd CSCs were isolated from vein leftovers of coronary artery bypass graft surgery and discarded atria

225 among Medicare beneficiaries undergoing any coronary artery bypass graft surgery and higher observed

226 h diabetes mellitus and multivessel disease, coronary artery bypass graft surgery and percutaneous co

227 (with percutaneous coronary intervention or coronary artery bypass graft surgery as appropriate) plu

228 Medicare data to compare change in rates of coronary artery bypass graft surgery between 2002 to 200

229 of a deleterious effect of P4P on access to coronary artery bypass graft surgery for high-risk patie

230 l infarction/cardiogenic shock (n=1705), and coronary artery bypass graft surgery groups.

231 without acute coronary syndromes or previous coronary artery bypass graft surgery in periods before (

232 had diabetes mellitus and underwent isolated coronary artery bypass graft surgery or percutaneous cor

233 oing a coronary revascularization procedure: coronary artery bypass graft surgery or percutaneous cor

234 ntly more complex, both clinically (previous coronary artery bypass graft surgery prevalence, 48% ver

235 Coronary artery bypass graft surgery rates for high-risk

236 Coronary artery bypass graft surgery rates for patients

237 artery (RA) can improve clinical outcomes in coronary artery bypass graft surgery remains unclear.

238 nts with no acute coronary syndrome/no prior coronary artery bypass graft surgery that were rated as

239 nsfection IV) analysis reported that EVH for coronary artery bypass graft surgery was associated with

240 Coronary artery bypass graft surgery was the only signif

241 Admissions after coronary artery bypass graft surgery were excluded.

242 MIs related to coronary artery bypass graft surgery were few, but numer

243 ysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to

244 Sixty patients undergoing coronary artery bypass graft surgery were randomized to

245 uitable collaterals, no smoking, no previous coronary artery bypass graft surgery, and left anterior

246 Death, myocardial infarction, coronary artery bypass graft surgery, and repeat PCI wer

247 harvesting (EVH) should be standard care in coronary artery bypass graft surgery, but vein quality a

248 L after AMI, including younger age, previous coronary artery bypass graft surgery, depressive symptom

249 al Health Insurance Database associated with coronary artery bypass graft surgery, myocardial infarct

250 found that high body mass index, history of coronary artery bypass graft surgery, number of treated

251 ed associated with lower mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-

252 ut lower rates of multivessel disease, prior coronary artery bypass graft surgery, prior MI, and smok

253 spital percutaneous coronary intervention or coronary artery bypass graft surgery, respectively.

254 death, angiogram-confirmed angina pectoris, coronary artery bypass graft surgery, stents, and angiop

255 myocardial infarction, coronary angioplasty, coronary artery bypass graft surgery, stroke).

256 who underwent cardiac interventions, such as coronary artery bypass graft surgery, were also included

257 Is; and 19 (1.6%) more sites were performing coronary artery bypass graft surgery.

258 ison with IV propofol for patient undergoing coronary artery bypass graft surgery.

259 onsortium (BARC) major bleeding unrelated to coronary artery bypass graft surgery.

260 risk of death and stroke when compared with coronary artery bypass graft surgery.

261 t greatest short-term risk of mortality with coronary artery bypass graft surgery.

262 onary intervention, or previous multi-vessel coronary artery bypass graft surgery.

263 isease, 218 (22%) were deemed ineligible for coronary artery bypass graft surgery.

264 llitus, and renal failure), and a history of coronary artery bypass graft surgery.

265 t patients (99%) were men, and 30% had prior coronary artery bypass graft surgery.

266 phically confirmed angina (1.91; 1.59-2.29), coronary artery bypass graft surgery/coronary angioplast

267 mained at higher risk for repeat procedures (coronary artery bypass graft surgery: 10.7% versus 6.8%,

268 for target vessel or target lesion failure (coronary artery bypass graft surgery: 8.9% versus 3.9%,

269 iac rehabilitation (CR) is recommended after coronary artery bypass graft surgery; however, the conse

270 analyzed 20 896 patients undergoing isolated coronary artery bypass grafting surgery at 33 medical ce

271 rs of 30-day all-cause readmission following coronary artery bypass grafting surgery by using nationa

272 icular, the low likelihood of ACEI/ARB after coronary artery bypass grafting surgery or in patients w

273 A coronary artery bypass grafting surgery readmission meas

274 l centers among patients undergoing isolated coronary artery bypass grafting surgery.

275 s focused on the use of drug eluting stents, coronary-artery bypass graft surgery and anti-thrombosis

276 Following coronary artery bypass grafting, there is a massive incr

277 There was a 3-fold increase in all non-coronary artery bypass graft Thrombolysis In Myocardial

278 f 283,131 patients who were readmitted after coronary artery bypass grafting, to 142,142 (83.2%) of 1

279 d a cohort matched 1:1 by age, sex, previous coronary artery bypass graft, transcatheter valve type,

280 Seventy patients undergoing coronary artery bypass grafting underwent an echocardiog

281 We randomly assigned 304 patients undergoing coronary artery bypass grafting using BITA to either in

282 Patients had a mix of coronary artery bypass grafting, valve surgery, and comb

283 Secondary end points included emergency coronary artery bypass grafting, vascular complications,

284 1); high-performing programs had higher mean coronary artery bypass grafting volumes (n = 241) than a

285 c reporting sites had higher mean annualized coronary artery bypass grafting volumes than nonreportin

286 ive atrial fibrillation within 30 days after coronary artery bypass graft was 2 of 30 patients (7%) i

287 ation (percutaneous coronary intervention or coronary artery bypass graft) was performed during index

288 , patient-level mortality rates for isolated coronary artery bypass grafting were consistently lower

289 esis 1 were randomized to medical therapy or coronary artery bypass grafting, whereas those in STICH

290 trial that enrolled patients with a previous coronary artery bypass graft who had developed at least

291 ndomized clinical trial, patients undergoing coronary artery bypass grafting with an internal mammary

292 th low ejection fraction who were undergoing coronary artery bypass grafting with cardiopulmonary byp

293 o 40% and scheduled for isolated or combined coronary artery bypass grafting with cardiopulmonary byp

294 omized to coronary artery bypass grafting or coronary artery bypass grafting with left ventricular re

295 who underwent primary, isolated multivessel coronary artery bypass grafting with the left internal t

296 studies comparing the long-term outcomes of coronary artery bypass grafting with the use of 2-arteri

297 tus by percutaneous coronary intervention or coronary artery bypass grafting within 7 days of the ind

298 ent angiography or revascularization (PCI or coronary artery bypass grafting) within 90 days.

299 with multivessel disease who are undergoing coronary artery bypass grafting without increased mortal

300 echocardiography), coronary angiography, or coronary artery bypass grafting (without angiography) as